FDA expands Winrevair’s label with HYPERION data, formalizes the use of non-animal testing methods, and Amgen reports positive Phase 3 results for dazodalibep in Sjögren disease.
|Articles|October 18, 2021
Avitide AVIPure® – AAV9 Residual Ligand Assay Kit (F970)
Author(s)Cygnus Technologies
The Avitide AVIPure® – AAV9 Residual Ligand Assay kits are intended for quantifying the AVIPure® – AAV9 Ligand.
The Avitide AVIPure® – AAV9 Residual Ligand Assay kits are intended for quantifying the AVIPure® – AAV9 Ligand. This kit incorporates a well-qualified sample treatment method to dissociate the ligand from the AAV virus.
AVIPure® – AAV9 Ligand, immobilized on various chromatography media, is used to purify AAV9 virus. Even when covalently attached, the ligand can leach off the chromatography support and co-elute with AAV9.
Residual AVIPure® – AAV9 Ligand must be minimized to avoid any adverse patient effects.
URL:
Related to this article
The FDA has approved a label update for Merck's Winrevair (sotatercept-csrk) incorporating Phase 3 HYPERION data, showing a 76% reduction in clinical worsening events when added to background therapy in adults diagnosed with pulmonary arterial hypertension within the past year.
BIIE CEO Dr Stephen Wilson outlines rapid growth plans and a multidisciplinary technology stack targeting global clinical translation.
FDA's new rule formally recognizes non-animal methods like organoids and AI models as valid ways to support human drug testing.
Dazodalibep hit its phase 3 primary endpoint at week 48, building on phase 2 data showing a 6.3-point ESSDAI reduction versus placebo.
Glycomine's GLM101, an investigational liposomal mannose-1-phosphate substrate replacement therapy, has received FDA Breakthrough Therapy designation for PMM2-CDG, a rare glycosylation disorder with no approved treatments.
How early Phase I decisions can shape or compromise the regulatory and financing outcomes that define a biotech program's future.
Novo Nordisk reports positive phase 3 CagriSema data, Biocon’s pertuzumab biosimilar gets a positive CHMP opinion under EMA’s new tailored pathway, and Vironexis reports complete responses with its one-time in vivo therapy for relapsed ALL.